Navigation Links
Clinical-trials Show Increased Therapeutic Activity of Pycnogenol than Daflon

A new research has found that Pycnogenol? is more effective than Daflon?, a combined form of diosmin and hesperidin commonly used to treat chronic venous insufficiency// (CVI).

According to the journal of Clinical and Applied Thrombosis/Hematosis, the supplementation of Pycnogenol? shows increased symptom reduction in the patients suffering from Chronic venous insufficiency. It is an antioxidant extracted from the bark of French maritime pine tree. The study led for 35 years shows its ability to improve blood flow and increase the strength of venous walls. Research shows Pycnogenol? more effective than Daflon?, a combined form of diosmin and hesperidin commonly used to treat CVI. The former drug is found to be more effective in treating the symptoms of CVI mainly edema, tight calves, skin alterations, pain during walking, and swelling limbs.

About 500,000 people in the United States develop leg ulcers due to CVI. If left untreated, leg and ankle swelling can lead to dangerous conditions such as deep vein thrombosis (DVT). Previous studies have shown Pycnogenol? to be effective in encouraging improved circulation and helping to prevent travel-related DVT. Like varicose veins, spider veins also develop if edema is left untreated.

"Chronic venous insufficiency is caused when leg veins cannot pump enough blood back into the heart. When people are not active, blood pools in their leg veins, legs and ankles can become swollen," said Peter Rohdewald, Ph.D. and researcher of the study. "Eventually, some of the valves cannot hold the weight of excessive blood, which then adds more pressure onto the next valve further downwards. Ultimately, the inability to prevent the liquid in the blood from seeping into the tissue is what causes edema, a common condition of CVI."

Researchers at L'Aquila University in Italy conducted a comparative analysis by supplementing 86 patients with severe CVI with Pycnogenol? and Daflon?. Each grou p supplemented daily for eight weeks. Patients who supplemented with Pycnogenol? received either 150 mg or 300 mg, while Daflon? patients supplemented with 1000 mg.

Ankle swelling was measured before 10 a.m. to avoid the swelling effect of standing and again after 30 minutes of resting with feet elevated. Measurements were taken at the beginning of the study and after four and eight weeks of treatment. A composite, analogue score based on signs and symptoms (edema, pain, restless limbs, subjective swelling, and skin alterations/redness) was recorded by patients. A second evaluation of edema was made by another physician.

After eight weeks of treatment, patients who supplemented with Pycnogenol? experienced decreased ankle swellings by 35 percent, while Daflon treatment decreased ankle swelling by 19 percent. A composite score for edema including pain, restless legs, feeling of heavy swollen legs, and skin alterations was found to be decreased with Pycnogenol? by 64%, whereas Daflon? was only half as effective, lowering the composite edema score by 32%.

The transdermal oxygen and carbon dioxide concentration in the lower legs was estimated with small sensors attached to the skin. Pycnogenol? treatment was found to significantly increase tissue oxygen and lower CO2, suggesting a considerable improvement in blood circulation to the legs. Daflon?, in contrast, did not yield any significant effect on the tissue oxygenation and apparently does not improve blood circulation to the legs.

"Interestingly, this study demonstrated that supplementation with a very high dosage of 300 mg Pycnogenol? a day did not yield significantly better effects than treatment with 150 mg Pycnogenol?, with the exception of the composite edema score, which improved better with the higher dosage," said Rohdewald.

Continuous stretching from CVI permanently enlarges veins. Past studies have shown that treating edema with Pycnogenol? prev ents the development of spider veins. Pycnogenol? also helps prevent existing spider veins from getting larger and more prominent. When edema is successfully treated, the increased pressure on veins gets normalized, preventing the veins from further increasing in size.

"Pycnogenol? has demonstrated its efficacy and safety in several clinical trials and symptoms of CVI have been reduced significantly by Pycnogenol? in controlled studies. We were pleased to see that not only did Pycnogenol? decrease CVI symptoms, but the results were significantly more successful then the prescription drug used for treating CVI," said Rohdewald.

(Source: Eurekalert)

Related medicine news :

1. Use of Cellular Phones associated with Increased risk of Brain Tumors
2. Increased Heart Attack Risk From Celebrex,Vioxx
3. Allergy Risk Increased by Kerosene Use
4. Fewer teeth & Increased Ischemic Stroke risk
5. Young Smokers at Increased Risk Of Developing a Heart Attack
6. Women With Diabetes At Increased Risk Of Developing Cognitive Impairment
7. Asbestos Exposure Associated With An Increased Risk For Autoimmune Disease
8. Schizophrenics On Medication At An Increased Risk For Developing Diabetes
9. Diabetics Found To Be At An Increased Risk Of Developing Cancer
10. Increased Risk For Venous Thrombosis In Cancer Patients
11. Increased risk of common infections in patients suffering from diabetes
Post Your Comments:

(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... According ... Vinci surgical robot is being more and more widely heralded as a breakthrough for ... da Vinci method has over traditional laparoscopic surgery is that it can greatly reduce ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm ... appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto ... Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock testified ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw ... and learning in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. ... For 65 years, Brillianteen has been a treasured tradition for numerous families in ...
(Date:11/25/2015)... ... November 25, 2015 , ... In ... nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension ... Pioneers, nominated by the public, will receive special recognition throughout 2016 as part ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a non-profit organization devoted ... as raising public awareness of the disorder while helping to bring expert medical ... $35,000 to bolster progress at the Tuberous Sclerosis Complex Center at Ann & ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
(Date:11/25/2015)... 2015 On Tuesday, November 24, 2015, ... against Wright Medical Technology, Inc. for product liability ... hip implant device, awarded $11 million in favor ... trial and three days of deliberations, the jury ... defectively designed and unreasonably dangerous, and that Wright ...
(Date:11/25/2015)... Allergan plc (NYSE: AGN ) today announced that it ... State Attorney General,s Office to end the litigation ... with the Attorney General over the decision of Forest Laboratories, ... the now generic version of memantine immediate release tablets.  Under ... its counterclaims against New York , and ...
Breaking Medicine Technology: